---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-168231"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:54:44.606538+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Amneal acquires Kashiv BioSciences for $750M upfront; raises FY2026 guidance on strong Q1

## Summary
- Acquisition of Kashiv: $375M cash + $375M equity (28.9M shares) at close; up to $350M regulatory milestones plus royalties.
- Expected close H2 2026; subject to shareholder and regulatory approvals; creates global biosimilar platform.
- Preliminary Q1 2026 results strong; standalone FY2026 guidance raised (details per press release).
- Transaction expected to deliver $400M-$500M in financial benefits; minimal impact on leverage.
- Restrictive covenants agreements with co-CEOs Chirag and Chintu Patel from closing through fifth anniversary.

## SEC filing metadata
- accession: 0001193125-26-168231
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/0001193125-26-168231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-168231
- JSON: https://secwatch.observer/filing/0001193125-26-168231.json
- Plain text: https://secwatch.observer/filing/0001193125-26-168231.txt

## Source-grounded claims
- claim_id: 53314320bfe85b15d73b931c5e161dc4f849fc46
  claim: Amneal Pharmaceuticals, Inc. updated its the first quarter ended March 31, 2026 guidance (raised).
  evidence_excerpt: On April 22, 2026, the Company issued a press release announcing its preliminary results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/0001193125-26-168231-index.htm
- claim_id: f117823fd34a48fc81a124a8f24ac98b8848cf8e
  claim: Amneal Pharmaceuticals, Inc. entered into Membership Interest Purchase Agreement with Kashiv BioSciences, LLC valued at $375,000,000 in cash (effective 2026-04-21).
  evidence_excerpt: On April 21, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Amneal”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”), pursuant to which, among other matters and on the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to acquire from the Sellers 100% of the outstanding membership interests of Kashiv (the “Acquisition”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/0001193125-26-168231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.